Q4 Earnings Forecast for SGMO Issued By HC Wainwright

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) – Analysts at HC Wainwright issued their Q4 2026 EPS estimates for Sangamo Therapeutics in a research note issued on Tuesday, August 12th. HC Wainwright analyst P. Trucchio expects that the biopharmaceutical company will post earnings of $0.01 per share for the quarter. HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Sangamo Therapeutics’ current full-year earnings is ($0.46) per share. HC Wainwright also issued estimates for Sangamo Therapeutics’ FY2029 earnings at $0.33 EPS.

SGMO has been the subject of a number of other reports. Wall Street Zen raised shares of Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Barclays reduced their price objective on shares of Sangamo Therapeutics from $9.00 to $5.00 and set an “overweight” rating for the company in a research note on Wednesday, May 14th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $4.50.

Sangamo Therapeutics Trading Up 7.4%

Shares of NASDAQ SGMO opened at $0.58 on Thursday. The firm has a 50 day moving average of $0.52 and a 200 day moving average of $0.71. The firm has a market capitalization of $174.99 million, a price-to-earnings ratio of -2.00 and a beta of 1.18. Sangamo Therapeutics has a 12-month low of $0.41 and a 12-month high of $3.18.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.01). The business had revenue of $18.31 million for the quarter, compared to the consensus estimate of $31.68 million. Sangamo Therapeutics had a negative net margin of 77.48% and a negative return on equity of 293.05%.

Institutional Trading of Sangamo Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Wasatch Advisors LP boosted its position in shares of Sangamo Therapeutics by 17.7% during the second quarter. Wasatch Advisors LP now owns 8,084,419 shares of the biopharmaceutical company’s stock worth $4,376,000 after acquiring an additional 1,215,653 shares during the last quarter. Engineers Gate Manager LP boosted its position in shares of Sangamo Therapeutics by 101.7% during the second quarter. Engineers Gate Manager LP now owns 87,425 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 44,078 shares during the last quarter. Invesco Ltd. boosted its position in shares of Sangamo Therapeutics by 40.6% during the second quarter. Invesco Ltd. now owns 680,452 shares of the biopharmaceutical company’s stock worth $368,000 after acquiring an additional 196,558 shares during the last quarter. XTX Topco Ltd bought a new position in shares of Sangamo Therapeutics during the second quarter worth $41,000. Finally, Geode Capital Management LLC boosted its position in shares of Sangamo Therapeutics by 2.1% during the second quarter. Geode Capital Management LLC now owns 2,332,279 shares of the biopharmaceutical company’s stock worth $1,263,000 after acquiring an additional 48,829 shares during the last quarter. 56.93% of the stock is owned by hedge funds and other institutional investors.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.